Vogenx, Inc. Form 10-Q — Sep 17, 2026
Vogenx reported a net loss of $384,430 for the second quarter of 2026, widening from $294,797 a year earlier, with six-month losses of $859,882 against no product revenue. The clinical-stage biotech held just $193,017 in cash at June 30, 2026 and carried a $1.78 million stockholders' deficit. The pivotal disclosure is the August 2026 IPO, in which the company sold 7,187,500 shares at $13.00 per share including full exercise of the underwriter's over-allotment option, generating approximately $84.9 million in net proceeds.
Key figures
- Revenue
- $0 (no revenue from product sales since inception)
- Total Debt
- 867700
- Total Assets
- 1409028
- Cash Position
- 193017
- Cash runway
- expected sufficient through 2028, provided substantial additional capital is raised before any Phase 3 trial
- Ipo shares sold
- 7187500
- Ipo net proceeds
- approximately $84.9 million
- Q2 2025 net loss
- 294797
- Q2 2026 net loss
- 384430
- Q2 2026 ga expense
- 198598
- Accumulated deficit
- approximately $11.7 million as of June 30, 2026
- Ipo price per share
- 13
- Q2 2026 rnd expense
- 156786
- Reverse split ratio
- 1-for-3 (approved July 21, 2026; effected July 28, 2026)
- Six month 2025 net loss
- 651416
- State nol carryforwards
- $9.6 million
- Federal nol carryforwards
- $9.4 million
- Ipo over allotment shares
- 937500
- Six month 2026 ga expense
- 423841
- Six month 2026 rnd expense
- 394695
- Shares converted at ipo closing
- 1951246
- Related party convertible notes principal
- $750,000 issued December 2025 at 12% interest
- Net cash used in operating activities 6m 2026
- approximately $323 thousand
Price after filing
Close on the filing date to close N calendar days later (from $34.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.